Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label follow-up of tenofovir amibufenamide in chronic hepatitis B
ChiCTR2100051284Phase 4Recruiting
- Sponsor
- Nanfang Hospital, Southern Medical University
- Start
- Sep 2021
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of tenofovir + amibufenamide in Chronic Hepatitis B (CHB), sponsored by Nanfang Hospital, Southern Medical University. Primary endpoint: Proportion of subjects with serum HBV DNA <20 IU/mL at Week 480. Started Sep 2021; status: recruiting.
02
Drugs
tenofovir + amibufenamide
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on ChiCTR2100051284.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100051284.